-
Acifran: Practical HCAR Signaling Workflows
2026-09-15
Build more interpretable lipid-receptor experiments with Acifran, from controlled cAMP assays to receptor-comparison studies. This workflow combines structural evidence, compound-handling guidance, and troubleshooting for lipid metabolism regulation research.
-
Bufalin: From Cardiotonic Steroid to Targeted Degrader
2026-09-15
Bufalin is moving from a broadly active cardiotonic steroid to a mechanistically testable oncology research tool. This article examines its apoptosis and differentiation biology, emerging STK33 degradation mechanism in triple-negative breast cancer, translational validation strategy, and the boundaries that researchers must address before clinical interpretation.
-
Atorvastatin Beyond Lipid Lowering: A Translational Playbook
2026-09-14
Atorvastatin is more than a cholesterol biosynthesis inhibitor. By perturbing the mevalonate pathway, it offers translational researchers a way to connect lipid flux, Ras and Rho signaling, vascular stress, and ferroptosis. This article interprets recent hepatocellular carcinoma evidence alongside cardiovascular models and presents a practical framework for designing, validating, and responsibly advancing Atorvastatin-based research hypotheses.
-
Cisapride (R 51619) in iPSC-CM Assay Design
2026-09-14
Cisapride (R 51619) connects hERG channel inhibition and 5-HT4 receptor pharmacology with modern cardiotoxicity screening. This guide translates deep-learning high-content imaging into practical assay-design decisions for cardiac electrophysiology research.
-
PDK4-IN-1 Hydrochloride: From Mechanism to Translation
2026-09-13
PDK4-IN-1 hydrochloride offers a selective way to investigate PDH activation, mitochondrial energy metabolism modulation, and glycolysis–TCA cycle regulation. This thought-leadership analysis connects the compound’s biochemical rationale with assay design, disease-model strategy, competitive positioning, and translational limitations.
-
L-Phenylephrine in α1A Receptor Research
2026-09-12
L-Phenylephrine is an adrenergic α1A receptor agonist for separating receptor-driven responses from broader cardiovascular stress signals. This practical guide connects sex-aware telemetry, cardiomyocyte assays, neural progenitor studies, and troubleshooting strategies while keeping acute receptor challenges distinct from chronic angiotensin II models.
-
LMP2A–mTORC1–GCNT3 Signaling in Nasopharyngeal Carcinoma
2026-09-12
The 2024 Virus Genes study identifies an LMP2A–mTORC1–GCNT3 regulatory axis in nasopharyngeal carcinoma, linking Epstein–Barr virus latency to glycosylation, epithelial–mesenchymal transition, migration, and proliferation. Its pathway-ordering experiments suggest that GCNT3 is both an mTORC1-responsive effector and a contributor to positive feedback, while the GCNT3–ZEB1 interaction provides a mechanistic explanation for enhanced cell motility.
-
Masitinib (AB1010): KIT/PDGFR Assay Guide
2026-09-11
Masitinib (AB1010) is a DMSO-compatible tyrosine kinase inhibitor for research involving KIT, PDGFRα, PDGFRβ, mast-cell responses, and selected GIST models. It is useful for controlled in vitro and in vivo study design, but should not be used in aqueous or ethanol-based workflows, assumed to be broad-spectrum, or treated as clinical evidence without independent validation.
-
Trypsin as a Translational Protease Control Point
2026-09-11
Trypsin is more than a routine protein digestion enzyme: as a serine protease, it offers a controllable way to connect peptide-bond chemistry with cell behavior, wound repair, inflammation, and viral membrane biology. This article outlines how translational researchers can use BA5744 to build better mechanistic assays while avoiding overinterpretation across biological domains.
-
GPR81 Signaling and Insulin-Independent Glucose Uptake
2026-09-10
The 2026 Cell Research study identifies lactate as an insulin-independent regulator of skeletal-muscle glucose uptake and defines a GPR81/FARP1/RAC1 pathway that promotes GLUT4 translocation. Its genetic, pharmacological, physiological, and human-association evidence positions lactate sensing as a potential complement to insulin-centered strategies for hyperglycemia research.
-
DAPT (GSI-IX): From Probe to Translational Platform
2026-09-10
DAPT (GSI-IX) is more than a γ-secretase inhibitor for pathway confirmation. Used with staged human organoid systems, it can help translational researchers separate APP and Notch biology, define exposure–response relationships, and build stronger evidence across neurodegeneration, oncology, immunology, and regenerative models.
-
Mestranol and Reversible Lysosomal Stress in Microglia
2026-09-09
The reference study identifies mestranol as a pharmacological trigger of a reversible lysosomal storage–like state in living zebrafish microglia. Its key contribution is separating preserved phagocytic uptake from impaired intracellular digestion, creating a tractable model for environmental neuroimmunotoxicity and microglial lysosomal stress.
-
ATRX Loss Sensitizes Glioma Cells to RTK Inhibitors
2026-09-09
The reference study shows that ATRX-deficient high-grade glioma cells are more vulnerable to several receptor tyrosine kinase and PDGFR inhibitors than ATRX-proficient counterparts. Its combination experiments further indicate that pairing these inhibitors with temozolomide may produce pronounced toxicity, supporting ATRX status as an important variable in glioma drug-response studies and clinical-trial interpretation.
-
Calpain Overactivation and Offspring Cognition After Surgery
2026-09-08
A 2025 Neuropharmacology study identifies excessive calpain activity as a mechanistic link between maternal non-obstetric surgery during pregnancy and later offspring cognitive deficits. Its intervention data suggest that postnatal calpain inhibition or TrkB activation can partially restore hippocampal synaptic markers, neuronal structure, and behavioral performance.
-
Azilsartan medoxomil monopotassium: Assay Guide
2026-09-08
Build reproducible AT1-receptor assays with Azilsartan medoxomil monopotassium (TAK 491), from DMSO stock preparation through pathway-specific functional readouts. The workflow combines nanomolar pharmacology with a clinically informed interpretation of angiotensin II vasopressor data without confusing receptor blockade with direct vasopressor conversion.